Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid CancerKeith C. Bible, Carol K. Wong-Clark, Electron Kebebew et al.|Thyroid|2021Cited by 699
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i> BRAF <sup>V600E</sup> </i> -Mutated Anaplastic Thyroid CarcinomaJennifer Wang, Maria E. Cabanillas, Mark Zafereo et al.|Thyroid|2019Cited by 229
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II StudyGlenn J. Hanna, Jochen H. Lorch, Naifa L. Busaidy et al.|Clinical Cancer Research|2018Cited by 125
American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatmentDavid C. Shonka, Gregory W. Randolph, Lori J. Wirth et al.|Head & Neck|2022Cited by 110